Popular

• 

  CME/CE In-Person Event

  Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology

  September 30, 2026

  Orlando, Florida

  Learn more

• 

  RestartResume

  Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors

  Cardiology

  Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors

  • 

    

    Joseph Rossano, MD

    Peer

• 

  RestartResume

  Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages

  CME/CE

  Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages

  • 

    

    Anton P. Porsteinsson, MD

    Peer

  • 

    

    Vijay K. Ramanan, MD, PhD

    Peer

  1.00 credits

• 

  RestartResume

  From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM

  MinuteCE®

  From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM

  • 

    

    Ahmad Masri, MD, MS

    Peer

  • 

    

    Anjali Owens, MD

    Peer

  1.00 program credits

• 

  RestartResume

  From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans

  MinuteCE®

  From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans

  • 

    

    Michael Nassif, MD, MSc

    Peer

  • 

    

    Anjali Owens, MD

    Peer

  1.00 program credits

• 

  RestartResume

  When ß-Blockers Fall Short in oHCM: Time for a New Approach?

  MinuteCE®

  When ß-Blockers Fall Short in oHCM: Time for a New Approach?

  • 

    

    Ahmad Masri, MD, MS

    Peer

  • 

    

    Anjali Owens, MD

    Peer

  1.00 program credits

• 

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  MinuteCE®

  The IgG Clock: Redose Using IgG Kinetics

  • 

    

    Christyn Edmundson, MD

    Peer

  • 

    

    Gil I. Wolfe MD, FAAN

    Peer

  1.00 program credits

• 

  RestartResume

  When to Begin FcRn: Initiation Criteria, Key Evidence

  MinuteCE®

  When to Begin FcRn: Initiation Criteria, Key Evidence

  • 

    

    Christyn Edmundson, MD

    Peer

  • 

    

    Gil I. Wolfe MD, FAAN

    Peer

  1.00 program credits

• 

  RestartResume

  Turning Flares Into Function: Flag Uncontrolled Disease

  MinuteCE®

  Turning Flares Into Function: Flag Uncontrolled Disease

  • 

    

    Christyn Edmundson, MD

    Peer

  • 

    

    Gil I. Wolfe MD, FAAN

    Peer

  1.00 program credits

• 

  RestartResume

  Minimal By Design: Define MSE Endpoints

  MinuteCE®

  Minimal By Design: Define MSE Endpoints

  • 

    

    Christyn Edmundson, MD

    Peer

  • 

    

    Gil I. Wolfe MD, FAAN

    Peer

  1.00 program credits

• 

  RestartResume

  Emerging Evidence: IgAN Disease-Modifying Agents

  MinuteCE®

  Emerging Evidence: IgAN Disease-Modifying Agents

  • 

    

    Richard Lafayette, MD, FACP

    Peer

  • 

    

    Hong Zhang

    Peer

  1.00 program credits

• 

  RestartResume

  Mechanism-Based Targeting: Why APRIL Matters in IgAN

  MinuteCE®

  Mechanism-Based Targeting: Why APRIL Matters in IgAN

  • 

    

    Suzuki Yusuke, MD, PhD

    Peer

  • 

    

    Dana Rizk, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice

  MinuteCE®

  Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice

  • 

    

    Prof. Dr. Johann Bauersachs

    Peer

  • 

    

    Carolyn S. P. Lam, MBBS, PhD

    Peer

  0.75 program credits

• 

  RestartResume

  Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event

  MinuteCE®

  Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event

  • 

    

    Prof. Dr. Johann Bauersachs

    Peer

  • 

    

    Carolyn S. P. Lam, MBBS, PhD

    Peer

  0.75 program credits

• 

  RestartResume

  Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors

  CME/CE

  Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors

  • 

    

    Mariana C. Castells, MD, PhD

    Peer

  • 

    

    Tsewang Tashi, MD

    Peer

  0.25 credits